Przejdź do zawartości

E7409

EPHA3 (571-end), active, GST tagged human

PRECISIO® Kinase, recombinant, expressed in baculovirus infected Sf9 cells, ≥70% (SDS-PAGE), buffered aqueous glycerol solution

Synonim(y):

ETK, HEK, TYRO4

Zaloguj się, aby wyświetlić ceny organizacyjne i kontraktowe.

Wybierz wielkość

Zmień widok

Informacje o tej pozycji

NACRES:
NA.32
UNSPSC Code:
51111800
Specific activity:
87-120 nmol/min·mg
Assay:
≥70% (SDS-PAGE)
Recombinant:
expressed in baculovirus infected Sf9 cells
Pomoc techniczna
Potrzebujesz pomocy? Nasz zespół doświadczonych naukowców chętnie Ci pomoże.
Pozwól nam pomóc


recombinant

expressed in baculovirus infected Sf9 cells

Quality Segment

product line

PRECISIO® Kinase

assay

≥70% (SDS-PAGE)

form

buffered aqueous glycerol solution

specific activity

87-120 nmol/min·mg

mol wt

~72 kDa

UniProt accession no.

shipped in

dry ice

storage temp.

−70°C

Gene Information

human ... EPHA3(2042)

General description

EPHA3 is a receptor tyrosine kinase (RTK) belonging to the largest subgroup of RTKs called ephrin group of receptors. It has a high level of expression from placental stage through the whole developmental process. It is a type I transmembrane protein, and has a membrane-bound ligand. It is both an oncogene and a tumor-suppressor gene. This protein resides in both the cytosol and the plasma membrane.

Biochem/physiol Actions

EPHA3 binds the ephrin-A ligand and has diverse cellular function. Analysis of human colorectal, breast, lung and pancreatic cancer samples shows somatic mutations in the EPHA3 gene. EPHA3 gene expression can be regulated by CD28 and IGF-1 in Jurkat cells and expression of EPHA3 is associated with adherence and motility of malignant T cells. It maintains the less differentiated state of cancer cells, by activating MAPK (mitogen-activated protein kinase) pathway. It is over-expressed in glioblastoma (GBM) cells, especially during the initial stages. It also has higher expression levels in aggressive mesenchymal subtype of GBM. In hepatocellular carcinoma (HCC), it predicts increased invasiveness and poor patient prognosis.

Physical form

Supplied in 50 mM Tris-HCl, pH 7.5, with 150 mM NaCl, 0.25 mM DTT, 0.1 mM EGTA, 0.1 mM EDTA, 0.1 mM PMSF, and 25% glycerol.

Legal Information

PRECISIO is a registered trademark of Merck KGaA, Darmstadt, Germany
Ta strona może zawierać tekst przetłumaczony maszynowo.


Klasa składowania

10 - Combustible liquids

wgk

WGK 1

flash_point_f

Not applicable

flash_point_c

Not applicable



Wybierz jedną z najnowszych wersji:

Certyfikaty analizy (CoA)

Lot/Batch Number

Nie widzisz odpowiedniej wersji?

Jeśli potrzebujesz konkretnej wersji, możesz wyszukać konkretny certyfikat według numeru partii lub serii.

Masz już ten produkt?

Dokumenty związane z niedawno zakupionymi produktami zostały zamieszczone w Bibliotece dokumentów.

Odwiedź Bibliotekę dokumentów